**Supplemental Table 1: Global Incidence, Prevalence and Mortality in Treated ESKD**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Country** | **Incidence,**  **crude (pmp)** | **Prevalence, crude (pmp)** | **Mortality Rate**  **(deaths/100py)** | **References** |
| Australiaa | 117 | 988 | Earlyb: 25  Latec: 14 | ([[1]](#endnote-1)) USRDS, 2018  ([[2]](#endnote-2)) Robinson, 2014  ([[3]](#endnote-3)) McDonald, 2015 |
| Argentina | 165 | 872 | First year: 18% (adjusted)  Annual: 16% (adjusted) | (1) USRDS, 2018  ([[4]](#endnote-4)) Orias, 2020 |
| Belgium  (French sp.) | 188 | 1310 | Early: 34  Late: 20 | (1) USRDS, 2018  (2) Robinson, 2014 |
| Brazil | 194 | 865 | Annual crude mortality  20% | ([[5]](#endnote-5)) Thomé, 2019  ([[6]](#endnote-6)) Sesso, 2020 |
| Canada | 200 | 1346 | Early: 25  Late: 17 | (1) USRDS, 2018  (2) Robinson, 2014 |
| Chile | 169 | 1382 | Annual crude  mortality  11% (HD), 13% (PD) | (1) USRDS, 2018  ([[7]](#endnote-7)) Ardiles, 2011 |
| France | 165 | 1278 | Early: 23  Late: 16 | (1) USRDS, 2018  (2) Robinson, 2014 |
| Germany | 65  (excluding transplantd) | 915  (excluding transplantd) | Early: 20  Late: 15 | (2) Robinson, 2014  ([[8]](#endnote-8)) Scholten, 2019  ([[9]](#endnote-9)) Potthoff, 2017 |
| Greece | 251 | 1284 | ERA-EDTA:  1 and 5-year crude survival  84% and 50% | (1) USRDS, 2018  ([[10]](#endnote-10)) Kramer, 2019 |
| Guatemala | 197 | 431 | \_ \_ | (1) USRDS, 2018 |
| Hong Kong | 171 | 1315 | \_ \_ | (1) USRDS, 2018 |
| Italy | 145 | 1150 | Early: 28  Late: 13 | (1) USRDS, 2018  (2) Robinson, 2014 |
| Japan | 296 | 2599 | Early: 17  Late: 5 | (1) USRDS, 2018  (2) Robinson, 2014 |
| Kuwait | 141 | 787 | \_ \_ | (1) USRDS, 2018 |
| Mexico (Jalisco) | 355 | 1447 | 11  Among patients initiated on PD | (1) USRDS, 2018  ([[11]](#endnote-11)) Garcia-Garcia, 2007 |
| Malaysia | 259 | 1352 | \_ \_ | (1) USRDS, 2018 |
| Netherlands | 117 | 1047 | ERA-EDTA:  1 and 5-year crude survival  84% and 50% | (1) USRDS, 2018  (10) Kramer, 2019 |
| Norway | 106 | 950 | ERA-EDTA:  1 and 5-year crude survival  84% and 50% | (1) USRDS, 2018  (10) Kramer, 2019 |
| Romania | 175 | 1038 | \_ \_ | (1) USRDS, 2018 |
| Russia | 58 | 303 | \_ \_ | (1) USRDS, 2018 |
| Singapore | 333 | 2076 | \_ \_ | (1) USRDS, 2018 |
| South Africa | 22 | 181 | \_ \_ | (1) USRDS, 2018 |
| South Korea | 311 | 1816 | 11.6  Among patients on HD or PD for at least 3 months | (1) USRDS, 2018  ([[12]](#endnote-12)) Kim, 2017 |
| Spain | 142 | 1234 | ERA-EDTA:  1 and 5-year crude survival  84% and 50% | (1) USRDS, 2018  (10) Kramer, 2019 |
| Sweden | 121 | 979 | Early: 28  Late: 20 | (1) USRDS, 2018  (2) Robinson, 2014 |
| Taiwan | 493 | 3392 | \_ \_ | (1) USRDS, 2018 |
| Thailand | 346 | 1515 | 1-year and 5-year PD patient survival: 83% and 54% | (1) USRDS, 2018  ([[13]](#endnote-13)) Changsirikulchai,  2018 |
| Turkey | 140 | 933 | \_ \_ | (1) USRDS, 2018 |
| United Kingdom | 120 | 956 | Early: 22  Late: 16 | (1) USRDS, 2018  (2) Robinson, 2014 |
| United States | 378 | 2196 | Early: 33  Late: 18 | (1) USRDS, 2018  (2) Robinson, 2014 |

**Supplemental Table 2: Global Variation in Kidney Replacement Therapy Modality, by Country and Gross Domestic Product per Capita, in 2016**

|  |  |  |  |
| --- | --- | --- | --- |
| **Country** | **GDP per Capita, PPP[[14]](#endnote-14)** | **Dialysis Modality1** | **Kidney Transplant1** |
| **High Income > $46,647/yr (GDP per Capita, PPP)** | | | |
| Singapore | $89,228 | in-center HD: 72%  home HD: 0%  PD: 10% | 18% |
| Norway | $58,934 | in-center HD: 24%  home HD: 0%  PD: 5% | 70% |
| United States | $57,928 | in-center HD: 63%  home HD: 1%  PD: 7% | 29% |
| Hong Kong | $57,229 | in-center HD: 16%  home HD: 2%  PD: 44%a | 38% |
| Netherlands | $52,283 | in-center HD: 30%  home HD: 2%  PD: 5% | 63% |
| Germany8,9 | $50,564 | HD: 94%  PD: 6%  (excludes transplant)b | -- |
| Sweden | $50,434 | in-center HD: 31%  home HD: 1%  PD: 9% | 58% |
| Taiwan | $49,100 | in-center HD: 88%  home HD: n/a  PD: 8% | 4% |
| Belgium  (French sp.) | $48,625 | in-center HD: 53%  home HD: 1%  PD: 4% | 41% |
| Australia | $47,350 | in-center HD: 38%  home HD: 5%  PD: 10% | 47% |
| **Upper Middle Income > $15,297/yr (GDP per Capita, PPP)** | | | |
| Canada | $46,441 | in-center HD: 44%  home HD: 3%  PD: 12% | 42% |
| Kuwait | $44,220 | in-center HD: 47%  home HD: 0%  PD: 7% | 46% |
| United Kingdom | $44,162 | in-center HD: 38%  home HD: 2%  PD: 6% | 54% |
| France | $42,922 | in-center HD: 51%  home HD: 0%  PD: 4% | 45% |
| Japan | $40,004 | in-center HD: 95%  home HD: 0%  PD: 3% | 3% |
| Italy | $39,918 | in-center HD: 56%  home HD: 0%  PD: 7% | 37% |
| South Korea | $37,317 | in-center HD: 73%  home HD: 0%  PD: 7% | 19% |
| Spain | $37,282 | in-center HD: 42%  home HD: 0%  PD: 5% | 52% |
| Greece | $27,823 | in-center HD: 76%  home HD: n/a  PD: 5% | 19% |
| Turkey | $26,329 | in-center HD: 75%  home HD: 1%  PD: 5% | 20% |
| Malaysia | $25,548 | in-center HD: 86%  home HD: 1%  PD: 10% | 4% |
| Romania | $24,316 | in-center HD: 85%  home HD: 0%  PD: 7% | 9% |
| Russia | $24,238 | in-center HD: 76%  home HD: n/a  PD: 5% | 19% |
| Chile | $22,701 | in-center HD: 80%  home HD: 0%  PD: 5% | 15% |
| Argentina | $20,153 | in-center HD: 72%  home HD: 0%  PD: 5% | 24% |
| Mexico (Jalisco) | $19,314 | in-center HD: 22%  home HD: 0%  PD: 35%c | 44% |
| Thailand | $16,577 | in-center HD: 66%  home HD: n/a  PD: 26%d | 8% |
| **Middle Income > $10,482/yr (GDP per Capita, PPP)** | | | |
|  |  |  |  |
| Brazil | $14,255 | in-center HD: 66%  home HD: 0%  PD: 5% | 30% |
| South Africa | $12,588 | in-center HD: 73%  home HD: n/a  PD: 13% | 14% |
| **Lower Middle Income > $6,180/yr (GDP per Capita, PPP)** | | | |
| Guatemala[[15]](#endnote-15) | $8,085 | HD: 40%  PD: 48%e | 12% |

**Supplemental Table Legend**

**Supplemental Table 1**: **Global Incidence, Prevalence and Mortality in Treated ESKD**: Incidence and prevalence data from 2016. Data for Canada exclude Quebec. Data for France exclude Martinique. Data for Guatemala exclude pediatric ESKD patients and patients receiving non-institutional KRT. Data for Italy representative of 35% (7 out of 19 regions) of ESKD patient population. Japan includes dialysis patients only. United Kingdom: England, Wales, Northern Ireland. European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) registries participating in mortality data include Austria, Belgium, Denmark, Finland, France, Greece, Iceland, Norway, Spain, Sweden, the Netherlands, and United Kingdom.

a Australia mortality data includes New Zealand.

b Early ≤120 days on dialysis.

c Late >365 days on dialysis.

d Claims data only cover 90% of the German dialysis population, as there are no accessible data on patients with private insurance.

pmp: per million general population. Deaths/100py: deaths per 100 patient-years. HD: hemodialysis. PD: peritoneal dialysis. sp: speaking

**Supplemental Table 2: Global Variation in Kidney Replacement Therapy Modality, by Country and Gross Domestic Product per Capita, in 2016**. Comparison of gross domestic product (GDP) per capita, based on purchasing power parity (PPP), to dialysis modality or kidney transplant. Data on 2016 GDP per capita, PPP expressed in international dollars obtained from the World Bank, International Comparison Program database. The income groups are based on GDP per capita, PPP. Dialysis modality and transplant data from USRDS unless otherwise referenced by country. Data for Canada exclude Quebec. Data for France exclude Martinique. Data for Italy representative of 35% (7 out of 19 regions) of ESRD patient population. United Kingdom: England, Wales, Northern Ireland.

a,c,d,e Denotes countries with a “PD First” Policy for KRT[[16]](#endnote-16)

b Claims data only cover 90% of the German dialysis population, as there are no accessible data on patients with private insurance.

HD: hemodialysis. PD: peritoneal dialysis. sp: speaking

1. United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018. [↑](#endnote-ref-1)
2. Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. *Kidney Int*. 2014;85(1):158‐165.  [↑](#endnote-ref-2)
3. McDonald SP. Australia and New Zealand Dialysis and Transplant Registry. *Kidney Int Suppl.* 2015;5(1):39-44. [↑](#endnote-ref-3)
4. Orias M, Rosa Diez GJ. Global dialysis perspective: Argentina. *Kidney360.* 2020;1:676-679. [↑](#endnote-ref-4)
5. Thomé FS, Sesso RC, Lopes AA, Lugon JR, Martins CT. Brazilian chronic dialysis survey 2017*. J Bras Nefrol*. 2019;41(2):208-214. [↑](#endnote-ref-5)
6. Sesso, Ricardo, Lugon JR. Global dialysis perspective: Brazil. *Kidney360*. 2020;1:216-219. [↑](#endnote-ref-6)
7. Ardiles LG, Poblete H, Ortiz M, et al. The health system in Chile: the nephrologist perspective. *J Nephrol.* 2011;24(2):149-54. [↑](#endnote-ref-7)
8. Scholten N, Ohnhaeuser T, Schellartz I, et al. Multidimensional analysis of factors responsible for the low prevalence of ambulatory peritoneal dialysis in Germany (MAU-PD): a cross-sectional Mixed-Methods Study Protocol. *BMJ Open*. 2019;9(4):e025451. [↑](#endnote-ref-8)
9. Potthoff F, Münscher C, Berendes A, *et al*. *Jahresbericht 2016 zur Qualität in der Dialyse*. Münster: MNC, 2017. [↑](#endnote-ref-9)
10. Kramer A, Pippias M, Noordzij M, et al. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary. *Clin Kidney J*. 2019;12(5):702‐720.  [↑](#endnote-ref-10)
11. Garcia-Garcia G, Briseño-Rentería G, Luquín-Arellan VH, et al. Survival among patients with kidney failure in Jalisco, Mexico. *J Am Soc Nephrol.* 2007;18(6):1922-7. [↑](#endnote-ref-11)
12. Kim HJ, Park JT, Han SH, et al. The pattern of choosing dialysis modality and related mortality outcomes in Korea: a national population-based study. *Korean J Intern Med*. 2017;32(4):699-710. [↑](#endnote-ref-12)
13. Changsirikulchai S, Sriprach S, Thokanit NS, et al. Survival Analysis and Associated Factors in Thai Patients on Peritoneal Dialysis Under the PD-First Policy. *Perit Dial Int*. 2018;38(3):172-178. [↑](#endnote-ref-13)
14. World Bank, International Comparison Program database. <https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?end=2016&most_recent_year_desc=true&start=1990&view=chart.> Accessed 24 June 2020. [↑](#endnote-ref-14)
15. Cusumano AM, Garcia-Garcia G, Gonzalez-Bedat MC, et al. Latin American Dialysis and Transplant Registry: 2008 prevalence and incidence of end-stage renal disease and correlation with socioeconomic indexes. *Kidney Int Suppl.* 2013;3(2):153-156. [↑](#endnote-ref-15)
16. Abraham G, Varughese S, Mathew M, Vijayan M. A review of acute and chronic peritoneal dialysis in developing countries. *Clin Kidney J*. 2015;8(3):310-7. [↑](#endnote-ref-16)